Accurately annotate the epitope specificity of T-cell receptor sequences with machine learning
Find and track the T cells that matter
Accelerate the development of your therapeutics and diagnostics by truly understanding T-cell responses. ImmuneWatch’s machine learning platform can annotate the epitope specificity of T-cell receptor (TCR) sequences, turning TCR repertoires into clinically actionable data.
ImmuneWatch DETECT
Extract therapy-, vaccine- or pathogen-specific TCRs from TCR repertoires to fully understand T-cell responses. Run ImmuneWatch’s machine learning platform on your own infrastructure or work with us to get the insights you need.
ImmuneWatch DESIGN
Find the right T cell epitopes and antigens for your vaccine with ImmuneWatch’s reverse vaccinology pipeline. Start from a protein or genome and get a ranked list of immunogenic epitopes or antigens.
How our technology works
TCR sequencing
TCR sequencing offers you an unprecedented deep insight in the composition of the T-cell receptor repertoire of a patient and its dynamics in response to a T-cell therapeutic or vaccine.
TCR sequencing can be performed on PBMCs, stimulated cells or tissue samples. ImmuneWatch’s technology is compatible with single cell or -bulk sequencing approaches.
Annotate the epitope specificity of TCRs
A bottle-neck in the analysis of TCR repertoires is the annotation of the epitope-specificity of TCRs. Based on > 7 years of research, ImmuneWatch has developed explainable machine learning algorithms (IMW-DETECT) that can link TCRs to their cognate epitope sequences. Find your therapy-, vaccine- or pathogen-specific TCRs in less than 2 minutes.
Immunoinformatic pipelines
ImmuneWatch is dedicated to offer a complete solution, from sequencing to immunoinformatics analysis. As experts in immunology and bioinformatics ImmuneWatch is able to provide a complete immunoinformatic pipeline from FASTQ to interactive reports.
Reverse vaccinology pipeline
Predict what parts of a pathogen will be most effective in a vaccine. ImmuneWatch’s unique algorithms provide not only insights in epitope presentation, but also into the prevalence of T cells that can potentially bind the peptide-MHC complexes (patent pending).
"Together with ImmuneWatch we were able to assess vaccine-induced T-cell signatures in our unique longitudinal sample collection of cancer patients. Based on antibody titers, it has previously been shown that cancer patients induce a weaker response towards COVID19 vaccines. T-cell immunity in this context is far less characterized and understood. Thanks to the ImmuneWatch DETECT platform we were able to take a deep dive into the SARS-CoV-2-specific T-cell response of our cancer patient cohort. "
Some of our latest insights
.gif)
Find the epitope-specificity of your TCRs today
